We have located links that may give you full text access.
Prediction of Tissue Outcome and Assessment of Treatment Effect in Acute Ischemic Stroke Using Deep Learning.
BACKGROUND AND PURPOSE: Treatment options for patients with acute ischemic stroke depend on the volume of salvageable tissue. This volume assessment is currently based on fixed thresholds and single imagine modalities, limiting accuracy. We wish to develop and validate a predictive model capable of automatically identifying and combining acute imaging features to accurately predict final lesion volume.
METHODS: Using acute magnetic resonance imaging, we developed and trained a deep convolutional neural network (CNNdeep ) to predict final imaging outcome. A total of 222 patients were included, of which 187 were treated with rtPA (recombinant tissue-type plasminogen activator). The performance of CNNdeep was compared with a shallow CNN based on the perfusion-weighted imaging biomarker Tmax (CNNTmax ), a shallow CNN based on a combination of 9 different biomarkers (CNNshallow ), a generalized linear model, and thresholding of the diffusion-weighted imaging biomarker apparent diffusion coefficient (ADC) at 600×10-6 mm2 /s (ADCthres ). To assess whether CNNdeep is capable of differentiating outcomes of ±intravenous rtPA, patients not receiving intravenous rtPA were included to train CNNdeep, -rtpa to access a treatment effect. The networks' performances were evaluated using visual inspection, area under the receiver operating characteristic curve (AUC), and contrast.
RESULTS: CNNdeep yields significantly better performance in predicting final outcome (AUC=0.88±0.12) than generalized linear model (AUC=0.78±0.12; P =0.005), CNNTmax (AUC=0.72±0.14; P <0.003), and ADCthres (AUC=0.66±0.13; P <0.0001) and a substantially better performance than CNNshallow (AUC=0.85±0.11; P =0.063). Measured by contrast, CNNdeep improves the predictions significantly, showing superiority to all other methods ( P ≤0.003). CNNdeep also seems to be able to differentiate outcomes based on treatment strategy with the volume of final infarct being significantly different ( P =0.048).
CONCLUSIONS: The considerable prediction improvement accuracy over current state of the art increases the potential for automated decision support in providing recommendations for personalized treatment plans.
METHODS: Using acute magnetic resonance imaging, we developed and trained a deep convolutional neural network (CNNdeep ) to predict final imaging outcome. A total of 222 patients were included, of which 187 were treated with rtPA (recombinant tissue-type plasminogen activator). The performance of CNNdeep was compared with a shallow CNN based on the perfusion-weighted imaging biomarker Tmax (CNNTmax ), a shallow CNN based on a combination of 9 different biomarkers (CNNshallow ), a generalized linear model, and thresholding of the diffusion-weighted imaging biomarker apparent diffusion coefficient (ADC) at 600×10-6 mm2 /s (ADCthres ). To assess whether CNNdeep is capable of differentiating outcomes of ±intravenous rtPA, patients not receiving intravenous rtPA were included to train CNNdeep, -rtpa to access a treatment effect. The networks' performances were evaluated using visual inspection, area under the receiver operating characteristic curve (AUC), and contrast.
RESULTS: CNNdeep yields significantly better performance in predicting final outcome (AUC=0.88±0.12) than generalized linear model (AUC=0.78±0.12; P =0.005), CNNTmax (AUC=0.72±0.14; P <0.003), and ADCthres (AUC=0.66±0.13; P <0.0001) and a substantially better performance than CNNshallow (AUC=0.85±0.11; P =0.063). Measured by contrast, CNNdeep improves the predictions significantly, showing superiority to all other methods ( P ≤0.003). CNNdeep also seems to be able to differentiate outcomes based on treatment strategy with the volume of final infarct being significantly different ( P =0.048).
CONCLUSIONS: The considerable prediction improvement accuracy over current state of the art increases the potential for automated decision support in providing recommendations for personalized treatment plans.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app